Overview of BCMA-directed therapies for multiple myeloma

On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Fredrik Schjesvold, Oslo University Hospital, Oslo, NO, provided an overview of B-cell maturation antigen (BCMA)-directed therapies in multiple myeloma (MM). During this presentation, Schjesvold provides an overview of currently available BCMA-directed therapies, including antibody–drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Schjesvold outlines differences in mechanisms of action, regulatory approvals, treatment settings, and key efficacy and safety data across approved agents. This independent educational activity was supported by GSK. All content was developed independently by SES in collaboration with the faculty. The funder was allowed no influence on the content of this activity. Hosted on Acast. See acast.com/privacy for more information.